Paragon Care Limited · ASX:PGC

Paragon Care — FY2022 Earnings Presentation

27 slides from Paragon Care's earnings presentation, Aug 25, 2022

Slide 1: FY22 Results – Paragon Care Limited
ParagonCare INVESTOR PRESENTATION 25 AUGUST 2022 FY22 Results Paragon Care Limited ASX: PGC
Slide 3: ParagonCare
ParagonCare
Slide 4: Strong foundation for growth
Strong foundation • Paragon Care represents an extremely attractive set of healthcare businesses which now have a strong for growth foundation for growth over the next 3-5 years Building a • Our ambition is to build a $100m EBITDA business over that timeframe through a combination of organic $100m E
Slide 5: Mainly driven by the inclusion of Quantum sales for five months
Mainly driven by the Mainly driven by the inclusion inclusion of Quantum of Quantum results for five sales for five months months FY22 growth in the original PGC Estimate on a pro forma basis business offset the funding $24m ex PGC and provided by JobKeeper in FY21 $10m ex Quantum This brings the fu
Slide 6: Integration activities are on track
• Integration activities are on track and the Quantum business ( now repositioned as Paragon Care Asia) is performing in line with expectations • John Walstab and Alan McCarthy have become directors of PGC and bring a wealth of experience to support PGC’s push into Asia • John Walstab will now focus
Slide 7: SMS acquisition
• NSW based, SMS supplies the pathology market, local specialist distributors and hospitals, predominantly in NSW and Queensland • SMS fits neatly into the existing Paragon Care ‘pillar’ structure with significant customer alignment so the acquisition is logical both in terms of strategic match and
Slide 8: FY22 Results
FY22 Results Stephen Munday Chief Financial Officer ParagonCare
Slide 10: Revenues increased in FY22 due to the inclusion of around $29m of Quantum
• Revenues increased in FY22 due to the inclusion of around $29m of Quantum sales; if Quantum sales are excluded: • Diagnostics Pillar sales were up $4m due to continued growth in core lines and further COVID swab medium sales • Service & Technology sales were steady with similar facility access iss
Slide 11: Working capital improvements across FY21 and FY22
Working capital improvements across FY21 and FY22 have been driven by continued focus on collections of receivables and management of inventories. FY21 FY22 Cash from operations $27.5m $19m In FY21 cashflow from operations far exceeding normal expected cash flows due to the work on collection of rec
Slide 14: Strategy and Growth
Strategy and Growth Mark Hooper Group CEO and Managing Director ParagonCare
Slide 19: Ophthalmology and optometry products
______________________________ Ophthalmology and optometry products including ophthalmic • surgical devices and diagnostic and vision testing equipment. • • • • _______________________________ Innovative surgical packs and • accessories. • • ______________________________ • Orthopaedics, pain manage
Slide 20: Immunohaemotology manufacture of a range of IVDs
_______________________________ Immunohaemotology manufacture of a range of IVDs, distribution of blood bank automation, OEM, and technical services. • • • _______________________________ Pathology equipment, reagents and • software. • • • _______________________________ • Laboratory and scientific
Slide 21: Service, support and technology management
_______________________________ Service, support and technology management. _______________________________ Infusion therapy, oncology, pharmacy, newborn and paediatric care, • orthopaedics, urology, veterinary, • pain management, diagnostics and critical care – Australia and New • Zealand. • ______
Slide 22: Service, support and technology management
_______________________________ Service, support and technology management. • • • • • _______________________________ Service, support and technology management. • • • _______________________________ Communication technology solutions for health and aged care with 24/7 national help-desk support. Pa
Slide 23: Clarity around strategy and improved execution
• The “light on the hill” provides clear context for PGC activities over the next 3-5 years Clarity around • The current focus for the pillars is to develop their own strategic plan which then supports a more actionable strategy and growth path beyond FY23 improved execution • This will generate a s
Slide 24: Appendix
Appendix ParagonCare
Slide 27: Thank You
Thank You

Paragon Care — FY2022 Earnings Presentation on 6ix

Paragon Care — FY2022 Earnings Presentation

Slide 1: FY22 Results – Paragon Care Limited

Slide 2: Paragon Care Ltd ASX:PGC | Copyright © 2022

Slide 3: ParagonCare

Slide 4: Strong foundation for growth

Slide 5: Mainly driven by the inclusion of Quantum sales for five months

Slide 6: Integration activities are on track

Slide 7: SMS acquisition

Slide 8: FY22 Results

Slide 9: Paragon Care Ltd ASX:PGC | Copyright © 2022

Slide 10: Revenues increased in FY22 due to the inclusion of around $29m of Quantum

Slide 11: Working capital improvements across FY21 and FY22

Slide 12: Paragon Care Ltd ASX:PGC | Copyright © 2022

Slide 13: Paragon Care Ltd ASX:PGC | Copyright © 2022

Slide 14: Strategy and Growth

Slide 15: Your partner in healthcare delivery

Slide 16: Paragon Care Ltd ASX:PGC | Copyright © 2022

Slide 17: Paragon Care Ltd ASX:PGC | Copyright © 2022

Slide 18: Paragon Care Ltd ASX:PGC | Copyright © 2022

Slide 19: Ophthalmology and optometry products

Slide 20: Immunohaemotology manufacture of a range of IVDs

Slide 21: Service, support and technology management

Slide 22: Service, support and technology management

Slide 23: Clarity around strategy and improved execution

Slide 24: Appendix

Slide 25: Paragon Care Ltd ASX:PGC | Copyright © 2022

Slide 26: Paragon Care Ltd ASX:PGC | Copyright © 2022

Slide 27: Thank You